Buparlisib, an inhibitor of a pan-isorform class I PI3K, taken orally, increased PFS in association with fulvestrant in postmenopausal women with advanced or metastatic estrogen receptor (ER) positive HER-2 negative breast cancer harboring PIK3CA mutations in a phase III clinical trial [121, 122]. This evidence concerns the gene PIK3CB and breast cancer.